OBJECTIVES: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis (MS), patient preferences will gain importance in the decision-making process. We assessed patients' implicit preferences for oral versus parenteral DMTs and identified factors influencing patients' treatment preference. METHODS: Patients with relapsing-remitting MS (n = 156) completed a questionnaire assessing treatment preferences, whereby they had to decide between pairs of hypothetical treatment scenarios. Based on this questionnaire a choice-based conjoint analysis was conducted. RESULTS: Treatment frequency and route of administration showed a stronger influence on patient preference compared with frequency of mild side effects. The latter attribute was more important for treatment-naïve patients compared with DMT-experienced patients. The higher the Extended Disability Status Scale score, the more likely pills, and the less likely fewer side effects were preferred. Pills were preferred over injections by 93% of patients, when treatment frequency and frequency of side effects were held constant. However, preference switched to injections when pills had to be taken three times daily and injections only once per week. Injections were also preferred when pills were associated with frequent side effects. CONCLUSIONS: Our results suggest that route of administration and treatment frequency play an important role in the patients' preference for a given DMT.
OBJECTIVES: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis (MS), patient preferences will gain importance in the decision-making process. We assessed patients' implicit preferences for oral versus parenteral DMTs and identified factors influencing patients' treatment preference. METHODS:Patients with relapsing-remitting MS (n = 156) completed a questionnaire assessing treatment preferences, whereby they had to decide between pairs of hypothetical treatment scenarios. Based on this questionnaire a choice-based conjoint analysis was conducted. RESULTS: Treatment frequency and route of administration showed a stronger influence on patient preference compared with frequency of mild side effects. The latter attribute was more important for treatment-naïve patients compared with DMT-experienced patients. The higher the Extended Disability Status Scale score, the more likely pills, and the less likely fewer side effects were preferred. Pills were preferred over injections by 93% of patients, when treatment frequency and frequency of side effects were held constant. However, preference switched to injections when pills had to be taken three times daily and injections only once per week. Injections were also preferred when pills were associated with frequent side effects. CONCLUSIONS: Our results suggest that route of administration and treatment frequency play an important role in the patients' preference for a given DMT.
Authors: M Ryan; D A Scott; C Reeves; A Bate; E R van Teijlingen; E M Russell; M Napper; C M Robb Journal: Health Technol Assess Date: 2001 Impact factor: 4.014
Authors: Dawn Stacey; Carol L Bennett; Michael J Barry; Nananda F Col; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; France Légaré; Richard Thomson Journal: Cochrane Database Syst Rev Date: 2011-10-05
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Edward J D Webb; David Meads; Ieva Eskyte; Natalie King; Naila Dracup; Jeremy Chataway; Helen L Ford; Joachim Marti; Sue H Pavitt; Klaus Schmierer; Ana Manzano Journal: Patient Date: 2018-08 Impact factor: 3.883
Authors: Larry D Lynd; Anthony Traboulsee; Carlo A Marra; Nicole Mittmann; Charity Evans; Kathy H Li; Melanie Carter; Celestin Hategekimana Journal: Ther Adv Neurol Disord Date: 2016-05-15 Impact factor: 6.570
Authors: Lindsay A Hampson; Isabel E Allen; Thomas W Gaither; Tracy Lin; Jie Ting; E Charles Osterberg; Leslie Wilson; Benjamin N Breyer Journal: Urology Date: 2016-09-16 Impact factor: 2.649
Authors: Lisa G Rider; Rohit Aggarwal; Angela Pistorio; Nastaran Bayat; Brian Erman; Brian M Feldman; Adam M Huber; Rolando Cimaz; Rubén J Cuttica; Sheila Knupp de Oliveira; Carol B Lindsley; Clarissa A Pilkington; Marilynn Punaro; Angelo Ravelli; Ann M Reed; Kelly Rouster-Stevens; Annet van Royen-Kerkhof; Frank Dressler; Claudia Saad Magalhaes; Tamás Constantin; Joyce E Davidson; Bo Magnusson; Ricardo Russo; Luca Villa; Mariangela Rinaldi; Howard Rockette; Peter A Lachenbruch; Frederick W Miller; Jiri Vencovsky; Nicolino Ruperto Journal: Ann Rheum Dis Date: 2017-05 Impact factor: 19.103